• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Addex

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · September 2, 2011

Addex Regains Rights to Parkinson’s Drug Candidates from Merck

Geneva, Switzerland, 2 September 2011 – Addex Pharmaceuticals (SIX:ADXN), a leading biopharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today …

News · July 27, 2011

Addex Pharmaceuticals First Half 2011 Financial Results

Geneva, Switzerland, 27 July 2011 – Addex Pharmaceuticals (SIX: ADXN), a leader in allosteric modulation-based drug discovery and development, announced today financial results for the first half of …

News · July 7, 2011

Addex Announces Corporate Reorganization and Restructuring Initiative to Strengthen Its Leadership Position in Allosteric Modulation-Based Drug Discovery and Development

Focus on Core R&D Programs Goals Include: Increased Operational Efficiency, Strategic Partnerships with Industry Leaders Geneva, Switzerland, 7 July 2011 - Allosteric modulation company Addex …

News · June 3, 2011

Addex Pharmaceuticals CEO Steps Down

Geneva, Switzerland, 3 June 2011 – Allosteric modulation company Addex Pharmaceuticals Ltd (SIX:ADXN) announced today that Vincent Mutel, PhD, has stepped down from his position as CEO of the Addex …

News · April 28, 2011

Addex Shareholders Appoint Hoyoung Huh and Oleg Nodelman to Board, Approve All Board Proposals at Annual General Meeting

Geneva, Switzerland, 28 April 2011 - Allosteric modulation company Addex Pharmaceuticals Ltd (SIX:ADXN) announced that its shareholders approved all the proposals of the board of directors at its 2011 …

News · March 31, 2011

Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID)

• Clinically validated mechanism of action for PD-LID • Second Phase IIa trial to begin this quarter with Addex allosteric modulators • Trial funded in part by Michael J. Fox Foundation for …

News · March 28, 2011

Addex Partner Starting Clinical Schizophrenia Trial

Geneva, Switzerland, March 28, 2011 – Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today the start of a Phase IIa clinical trial of ADX71149 for the treatment of …

News · March 14, 2011

Addex Converts Mandatory Convertible Notes and Issues Ordinary Shares

Geneva, Switzerland, 14 March, 2011 – Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today that further to the Company’s press release dated 14 September 2010, the …

News · March 9, 2011

Addex Board Proposes Hoyoung Huh and Oleg Nodelman for Election to the Board of Directors

Geneva, Switzerland, 9 March 2011 – Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today that the Board of Directors proposes to the Annual General Meeting of 28 April 2011 …

News · February 23, 2011

Addex Pharmaceuticals 2010 Financial Results

Geneva, Switzerland, 23 February 2011 – Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today 2010 financial results and reviewed the status of its pipeline. The results will …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact